Urothelial carcinoma trial updates from ASCO 2018

Bradley McGregor, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses exciting urothelial carcinoma therapy updates from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. Dr McGregor covers results and updates from: the comparison of nab-paclitaxel and paclitaxel in the advanced setting (NCT02033993); the Phase I EV-101 study of enfortumab vedotin (NCT02091999) in platinum-refractory patients; the Phase II EV-201 study (NCT03219333) in platinum-refractory and naive patients; and the Phase II study of erdafitinib (NCT02365597) in patients with metastatic or unresectable disease with FGFR alterations. He also highlights the importance of continuing research to prevent disease progression, mentioning two studies investigating atezolizumab (ABACUS; NCT02662309) and pembrolizumab (PURE-01; NCT02736266) in the neoadjuvant setting.